Momenta Pharmaceuticals (NASDAQ:MNTA) Downgraded by ValuEngine to Sell

Share on StockTwits

Momenta Pharmaceuticals (NASDAQ:MNTA) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Friday, ValuEngine reports.

MNTA has been the topic of a number of other research reports. BidaskClub lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 9th. Cantor Fitzgerald reiterated a “buy” rating and issued a $25.00 target price on shares of Menlo Therapeutics in a research report on Thursday, May 2nd. Finally, Zacks Investment Research lowered Farmers & Merchants Bancorp, Inc. (OH) from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 9th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $22.23.

Momenta Pharmaceuticals stock traded down $0.55 during trading hours on Friday, reaching $9.60. The stock had a trading volume of 326,123 shares, compared to its average volume of 538,663. The company has a market capitalization of $946.68 million, a P/E ratio of -4.73 and a beta of 2.13. The stock has a 50 day moving average of $11.83. Momenta Pharmaceuticals has a 52 week low of $9.55 and a 52 week high of $32.20.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.01). Momenta Pharmaceuticals had a negative return on equity of 43.98% and a negative net margin of 231.49%. The business had revenue of $4.11 million for the quarter, compared to analysts’ expectations of $10.12 million. During the same quarter in the previous year, the firm posted ($0.63) EPS. Momenta Pharmaceuticals’s revenue was down 15.3% on a year-over-year basis. Research analysts predict that Momenta Pharmaceuticals will post -1.79 EPS for the current year.

In other Momenta Pharmaceuticals news, SVP Santiago Arroyo sold 2,531 shares of the company’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $15.00, for a total value of $37,965.00. Following the sale, the senior vice president now owns 19,272 shares in the company, valued at approximately $289,080. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Jo Ann Beltramello sold 13,672 shares of the company’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $15.00, for a total value of $205,080.00. Following the completion of the sale, the insider now owns 68,494 shares in the company, valued at approximately $1,027,410. The disclosure for this sale can be found here. In the last quarter, insiders sold 63,784 shares of company stock worth $868,941. 3.40% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. Quantamental Technologies LLC purchased a new stake in Momenta Pharmaceuticals in the 1st quarter worth approximately $68,000. Marshall Wace North America L.P. purchased a new stake in Momenta Pharmaceuticals in the 1st quarter worth approximately $130,000. Amalgamated Bank purchased a new stake in Momenta Pharmaceuticals in the 4th quarter worth approximately $136,000. CWM Advisors LLC boosted its position in Momenta Pharmaceuticals by 17.2% in the 2nd quarter. CWM Advisors LLC now owns 13,780 shares of the biotechnology company’s stock worth $172,000 after purchasing an additional 2,020 shares in the last quarter. Finally, Everence Capital Management Inc. purchased a new stake in Momenta Pharmaceuticals in the 1st quarter worth approximately $214,000. Institutional investors and hedge funds own 97.43% of the company’s stock.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

See Also: Capital Gains Distribution

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Pioneer Energy Services  Lowered to Sell at Zacks Investment Research
Pioneer Energy Services Lowered to Sell at Zacks Investment Research
Nice  Downgraded by BidaskClub
Nice Downgraded by BidaskClub
Redfin  Lifted to Buy at BidaskClub
Redfin Lifted to Buy at BidaskClub
SS&C Technologies  Upgraded by BidaskClub to Strong-Buy
SS&C Technologies Upgraded by BidaskClub to Strong-Buy
Svb Leerink Upgrades ACADIA Pharmaceuticals  to “Outperform”
Svb Leerink Upgrades ACADIA Pharmaceuticals to “Outperform”
Broadcom  Downgraded to “Hold” at Loop Capital
Broadcom Downgraded to “Hold” at Loop Capital


 
© 2006-2019 Zolmax.